The role of interleukin-17A in colorectal tumorigenesis

Cancer Biotherapy and Radiopharmaceuticals

Volumn 28, Issue 6, 2013, Pages 429-432

  Shi, Yingpeng ^a   Lin, Hui ^b   Cui, Jing ^a   Qi, Haili ^a   Florholmen, Jon ^c   Liu, Zhanju ^b   Cui, Guanglin ^a,c  

^a ZHENGZHOU UNIVERSITY   (China)

^b TENTH PEOPLE S HOSPITAL OF TONGJI UNIVERSITY   (China)

^c UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

Colorectal; IL 17A; Tumorigenesis

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 17; INTERLEUKIN 17ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 21; INTERLEUKIN 23; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COLON CARCINOGENESIS; COLORECTAL ADENOMA; COLORECTAL CANCER; DISEASE SEVERITY; GENE EXPRESSION PROFILING; HUMAN; MISMATCH REPAIR; NONHUMAN; PRECANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REVIEW; SURVIVAL RATE; TH17 CELL; TUMOR MICROENVIRONMENT;

ANIMALS; CARCINOGENESIS; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; HUMANS; INTERLEUKIN-17; TUMOR MARKERS, BIOLOGICAL;

EID: 84880900443     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2012.1396     Document Type: Review

References (48)

1. Atreya R, Neurath MF. Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer. Clin Rev Allergy Immunol 2005;28:187.
2. Fantini MC, Pallone F. Cytokines: From gut inflammation to colorectal cancer. Curr Drug Targets 2008;9:375.
3. Chung YC, Chang YF. Significance of inflammatory cytokines in the progression of colorectal cancer. Hepatogastroenterology 2003;50:1910.
4. Wilson J, Balkwill F. The role of cytokines in the epithelial cancer microenvironment. Semin Cancer Biol 2002;12:113.
5. Yuan A, Chen JJ, Yao PL, et al. The role of interleukin-8 in cancer cells and microenvironment interaction. Front Biosci 2005;10:853.
6. Waldner MJ, Neurath MF. Colitis-associated cancer: The role of T cells in tumor development. Semin Immunopathol 2009;31:249.
7. Kidd P. Th1/Th2 balance: The hypothesis, its limitations, and implications for health and disease. Altern Med Rev 2003;8:223.
8. Contasta I, Berghella AM, Pellegrini P, et al. Passage from normal mucosa to adenoma and colon cancer: Alteration of normal sCD30 mechanisms regulating TH1/TH2 cell functions. Cancer Biother Radiopharm 2003;18:549.
9. Cui G, Goll R, Olsen T, et al. Reduced expression of microenvironmental Th1 cytokines accompanies adenomascarcinomas sequence of colorectum. Cancer Immunol Immunother 2007;56:985.
10. Korn T, Bettelli E, Oukka M, et al. IL-17 and Th17 Cells. Annu Rev Immunol 2009;27:485.
11. Hinrichs CS, Kaiser A, Paulos CM, et al. Type 17 CD8+T cells display enhanced antitumor immunity. Blood 2009; 114:596.
12. Kryczek I, Wu K, Zhao E, et al. IL-17 + regulatory T cells in the microenvironments of chronic inflammation and cancer. J Immunol 2011;186:4388.
13. Weaver CT, Hatton RD, Mangan PR, et al. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007;25:821.
14. Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003; 52:65.
15. Olsen T, Rismo R, Cui G, et al. TH1 and TH17 interactions in untreated inflamed mucosa of inflammatory bowel disease, and their potential to mediate the inflammation. Cytokine 2011;56:633.
16. Liu Z, Yadav PK, Xu X, et al. The increased expression of IL-23 in inflammatory bowel disease promotes intraepithelial and lamina propria lymphocyte inflammatory responses and cytotoxicity. J Leukoc Biol 2011;89:597.
17. Murugaiyan G, Saha B. Protumor vs antitumor functions of IL-17. J Immunol 2009;183:4169.
18. Numasaki M, Fukushi J, Ono M, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003;101: 2620.
19. Martin-Orozco N, Dong C. The IL-17/IL-23 axis of inflammation in cancer: Friend or foe? Curr Opin Investig Drugs 2009;10:543.
20. Kryczek I, Wei S, Szeliga W, et al. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 2009;114:357.
21. Muranski P, Boni A, Antony PA, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008;112:362.
22. Klintrup K, Makinen JM, Kauppila S, et al. Inflammation and prognosis in colorectal cancer. Eur J Cancer 2005;41: 2645.
23. Nam JS, Terabe M, Kang MJ, et al. Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res 2008;68:3915.
24. Chae WJ, Gibson TF, Zelterman D, et al. Ablation of IL-17A abrogates progression of spontaneous intestinal tumorigenesis. Proc Natl Acad Sci U S A 2010;107:5540.
25. Hyun YS, Han DS, Lee AR, et al. Role of IL-17A in the development of colitis-associated cancer. Carcinogenesis 2012;33:931.
26. Le Gouvello S, Bastuji-Garin S, Aloulou N, et al. High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. Gut 2008;57:772.
27. Becker C, Fantini MC, Wirtz S, et al. IL-6 signaling promotes tumor growth in colorectal cancer. Cell Cycle 2005;4:217.
28. Yang L, Pang Y, Moses HL. TGF-beta and immune cells: An important regulatory axis in the tumor microenvironment and progression. Trends Immunol 2010;31:220.
29. Liu J, Duan Y, Cheng X, et al. IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun 2011;407:348.
30. Leslie A, Carey FA, Pratt NR, et al. The colorectal adenomacarcinoma sequence. Br J Surg 2002;89:845.
31. Cui G, Yuan A, Goll R, Florholmen J. IL-17A in the tumor microenvironment of the human colorectal adenomacarcinoma sequence. Scand J Gastroenterol 2012;47:1304.
32. Wågsäter D, Lofgren S, Hugander A, et al. Expression of interleukin-17 in human colorectal cancer. Anticancer Res 2006;26:4213.
33. Fox SH, Whalen GF, Sanders MM, et al. Angiogenesis in normal tissue adjacent to colon cancer. J Surg Oncol 1998; 69:230.
34. Pandey S, Gordon PH, Wang E. Expression of proliferationspecific genes in the mucosa adjacent to colon carcinoma. Dis Colon Rectum 1995;38:462.
35. Cui G, Yuan A, Goll R, et al. Distinct changes of dendritic cell number and IL-12 mRNA level in adjacent mucosa throughout the colorectal adenoma-carcinoma sequence. Cancer Immunol Immunother 2007;56:1993.
36. Chang SH, Dong C. IL-17F: Regulation, signaling and function in inflammation. Cytokine 2009;46:7.
37. Yang XO, Chang SH, Park H, et al. Regulation of inflammatory responses by IL-17F. J Exp Med 2008;205:1063.
38. Tong Z, Yang XO, Yan H, et al. A protective role by interleukin-17F in colon tumorigenesis. PLoS One 2012;7: e34959.
39. Benchetrit F, Ciree A, Vives V, et al. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 2002;99:2114.
40. Tartour E, Fossiez F, Joyeux I, et al. Interleukin 17, a T-cellderived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res 1999;59:3698.
41. Wang L, Yi T, Kortylewski M, et al. Y. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 2009;206:1457.
42. Sitohy B, Nagy JA, Dvorak HF. Anti-VEGF/VEGFR therapy for cancer: Reassessing the target. Cancer Res 2012;72:1909.
43. Takahashi H, Numasaki M, Lotze MT, et al. Interleukin-17 enhances bFGF-, HGF- and VEGF-induced growth of vascular endothelial cells. Immunol Lett 2005;98:189.
44. Inozume T, Hanada K, Wang QJ, et al. IL-17 secreted by tumor reactive T cells induces IL-8 release by human renal cancer cells. J Immunother 2009;32:109.
45. Cui G, Yuan A, Goll R, et al. Dynamic changes of interleukin-8 network along the colorectal adenoma-carcinoma sequence. Cancer Immunol Immunother 2009;58:1897.
46. Radosavljevic G, Ljujic B, Jovanovic I, et al. Interleukin-17 may be a valuable serum tumor marker in patients with colorectal carcinoma. Neoplasma 2010;57:135.
47. Yang S, Wang B, Guan C, et al. Foxp3+IL-17+T cells promote development of cancer-initiating cells in colorectal cancer. J Leukoc Biol 2011;89:85.
48. Zhang Q, Yamaza T, Kelly AP, et al. Tumor-like stem cells derived from human keloid are governed by the inflammatory niche driven by IL-17/IL-6 axis. PLoS One 2009; 4:e7798.